Received May 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
The patient received the first and second dose but never recived her 3rd dose.; No additional AE reported.; This spontaneous report has been received from an other health professional, regarding to a 27-year-old female patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, and previous drug reactions or allergies were not reported. On an unknown date in December 2017, the patient received the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), then on an unspecified date in March 2018, she received the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), both doses administered as prophylaxis (doses, routes of administration, anatomical sites of injection, vaccination schemes frequency, lot numbers and expiration dates were not reported). Also, it was reported that the patient never received her 3rd dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (Inappropriate schedule of product administration). No additional adverse events were reported in the patient.